We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA halts then allows sales of Ariad's leukemia medication.
- Authors
Senior, Melanie
- Abstract
The article focuses on the impact of the decision of the U.S. Food and Drug Administration (FDA) to suspend the marketing of chronic myeloid leukemia (CML) drug Iclusig (ponatinib) from Ariad Pharmaceuticals Inc. in late October 2013 to pharmaceutical industry. Topics discussed include basis of the FDA on suspending the drug into the market, drug withdrawal policy, and impact of the withdrawal to the operation of Ariad.
- Subjects
UNITED States; UNITED States. Food &; Drug Administration; PHARMACEUTICAL policy; ARIAD Pharmaceuticals Inc.; TREATMENT of chronic myeloid leukemia; INDUSTRIES; PHARMACEUTICAL industry
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 1, p9
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0114-9a